Rubius Therapeutics, Inc.
rubiustx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2022 10-K, filed Feb 27, 2023. Its latest SEC filing is a 15-12G from Apr 10, 2023.
10-K for FY2022, filed Feb 27, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops red blood cell-based cellular medicines for patients with cancer and autoimmune diseases.
10-K for FY2022, filed Feb 27, 2023We are a biopharmaceutical company that has developed a platform and pipeline focused on creating an entirely new class of cellular…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2022, filed Feb 27, 2023
How Were They Changing?
-
Apr 6, 2023
Stockholders approved the company's liquidation and dissolution
The approval authorizes the Board to liquidate and dissolve the company under its plan.
Sources
8-K, filed Apr 6, 2023
On April 6, 2023, at a special meeting of stockholders (the “Special Meeting”) of the Company, the Company’s stockholders approved the…View ↗
-
Mar 3, 2023
Company withdrew delisting appeal and CEO's employment ended
Nasdaq said trading would be suspended after the withdrawal, and the CEO's employment ended.
Sources
8-K, filed Mar 3, 2023
On March 3, 2023, the Company informed the Staff of its decision to withdraw its request for a hearing before the Panel (the “Withdrawal”).…View ↗
A different cell-making approach
The earlier platform genetically engineered precursor cells and cultured them into reticulocytes; the latest report describes chemically attaching payloads to blood-banked red cells.
10-K for FY2019, filed Mar 12, 2020 10-K for FY2022, filed Feb 27, 2023The RED PLATFORM allows us to generate a wide variety of allogeneic, ready‑to‑use RCT product candidates with a universal and proprietary…View ↗
Loading...
